Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive

Date Published: 


Datamonitor forecasts that the insulin antidiabetics market will grow from 10.6 billion in 2009 to $16.4 billion in 2019 for the seven major markets, with pipeline products contributing 18% of sales. Basal insulin analog Degludec (Novo Nordisk) will be the dominant pipeline entrant, while MannKind's inhaled insulin Afrezza is forecast to gain only a small share of the prandial insulin market.
Features and benefits

* Comprehensive analysis of the current insulin antidiabetic pipeline including both reformulations of marketed insulins and novel analog products.* A detailed clinical and commercial assessment of all key emerging therapies.* Sales forecasts for key late-stage developmental insulin antidiabetic agents in the seven major markets to 2019.* Analysis of unmet needs in insulin therapies and key development R&D strategies including alternative delivery methods and new clinical profiles.

A diabetes epidemic is sweeping the Western World as changes in diet and lifestyle lead to a sedentary obese population at risk of diabetes. All type 1 diabetes patients need insulin therapy and a majority of type 2 patients eventually fail on non-insulin treatment and use insulins, so the insulin market is increasing.Most of the insulin pipeline candidates are reformulations of marketed insulins to improve clinical characteristics or ease of use, being developed by small niche players. Insulin specialist Novo Nordisk is developing novel insulin analogs, while only two candidates come from Big Pharma companies.Datamonitor expects the basal insulin Degludec (insulin degludec, Novo Nordisk) to be a strong competitor for class leader Lantus. The pipeline basal insulin is forecast to reach blockbuster status with US sales above $1 billion by 2016. DegludecPlus, the fixed-ratio combination of Degludec with NovoRapid, will be less successful.
Your key questions answered

* Quantify the sales of pipeline drugs in the insulin antidiabetic market.* Identify licensing opportunities based on company portfolio and market needs.* Assess the remaining market opportunities and barriers to uptake for novel insulin therapies and formulations.